CRIS Curis Inc

Price (delayed)

$10.87

Market cap

$64.07M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.96

Enterprise value

$40.18M

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of ...

Highlights
CRIS's debt is down by 29% YoY and by 10% from the previous quarter
Curis's EPS has increased by 26% YoY and by 3.1% QoQ
The equity has plunged by 58% YoY and by 34% from the previous quarter
CRIS's quick ratio has dropped by 51% year-on-year and by 16% since the previous quarter

Key stats

What are the main financial stats of CRIS
Market
Shares outstanding
5.89M
Market cap
$64.07M
Enterprise value
$40.18M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.25
Price to sales (P/S)
5.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.01
Earnings
Revenue
$10.02M
EBIT
-$47.41M
EBITDA
-$45.81M
Free cash flow
-$38.43M
Per share
EPS
-$8.96
Free cash flow per share
-$7.26
Book value per share
$3.34
Revenue per share
$1.89
TBVPS
$12.9
Balance sheet
Total assets
$77.28M
Total liabilities
$57.61M
Debt
$2.79M
Equity
$19.67M
Working capital
$47.39M
Liquidity
Debt to equity
0.14
Current ratio
4.51
Quick ratio
4.37
Net debt/EBITDA
0.52
Margins
EBITDA margin
-457.1%
Gross margin
97.9%
Net margin
-473%
Operating margin
-482.2%
Efficiency
Return on assets
-54.8%
Return on equity
-169.2%
Return on invested capital
-108.1%
Return on capital employed
-74.4%
Return on sales
-473%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRIS stock price

How has the Curis stock price performed over time
Intraday
0%
1 week
0.37%
1 month
11.26%
1 year
-2.96%
YTD
-14.75%
QTD
-14.75%

Financial performance

How have Curis's revenue and profit performed over time
Revenue
$10.02M
Gross profit
$9.81M
Operating income
-$48.33M
Net income
-$47.41M
Gross margin
97.9%
Net margin
-473%
The net income is up by 16% year-on-year
CRIS's net margin is up by 15% YoY but it is down by 2.7% from the previous quarter
Curis's operating income has increased by 9% YoY but it has decreased by 4.3% QoQ
CRIS's operating margin is up by 8% year-on-year but it is down by 6% since the previous quarter

Growth

What is Curis's growth rate over time

Valuation

What is Curis stock price valuation
P/E
N/A
P/B
3.25
P/S
5.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.01
Curis's EPS has increased by 26% YoY and by 3.1% QoQ
The equity has plunged by 58% YoY and by 34% from the previous quarter
The price to book (P/B) is 35% higher than the last 4 quarters average of 2.4
CRIS's price to sales (P/S) is 73% lower than its 5-year quarterly average of 21.1 and 4.3% lower than its last 4 quarters average of 6.0

Efficiency

How efficient is Curis business performance
CRIS's return on equity has dropped by 79% year-on-year and by 25% since the previous quarter
The ROIC has plunged by 59% YoY and by 26% from the previous quarter
The company's return on assets fell by 21% YoY and by 10% QoQ
Curis's return on sales has increased by 15% YoY but it has decreased by 2.7% QoQ

Dividends

What is CRIS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRIS.

Financial health

How did Curis financials performed over time
The company's total assets is 34% higher than its total liabilities
CRIS's quick ratio has dropped by 51% year-on-year and by 16% since the previous quarter
The current ratio has dropped by 51% year-on-year and by 16% since the previous quarter
CRIS's debt is 86% less than its equity
The debt to equity has soared by 75% YoY and by 40% QoQ
The equity has plunged by 58% YoY and by 34% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.